Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ConjuChem Biotechnologies has initiated dosing in its Phase II clinical study for the treatment of Type 2 diabetes using the company's proprietary PC-DAC:Exendin-4 compound. The study is the first of two Phase II studies that the company plans to conduct concurrently.
Subscribe to our email newsletter
This Phase II trial, a randomized, double-blind, placebo-controlled, multiple dose study, will evaluate the efficacy and safety of three months of weekly injections of PC-DAC:Exendin-4 in patients with Type 2 diabetes not adequately controlled by metformin monotherapy. The trial will enroll 90 patients with 30 patients randomized to one of three parallel treatment groups: a 1.5mg fixed weekly dose group, a group receiving a 1.5mg weekly dose titrating to 2mg at the fifth week, and a placebo group.
A second Phase II trial is also planned which will be a randomized, double-blind, placebo-controlled, multiple dose study, to evaluate the efficacy and safety of three months treatment with PC-DAC:Exendin-4 in Type 2 diabetes patients not adequately controlled by metformin monotherapy. This trial is designed to explore the efficacy and safety profile of twice-weekly titration and maintenance dosing and is expected to begin later in the first quarter of 2008.